TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $3.22M fell 2.4% year over year, behind the -1.7% change in trailing-twelve-month research & development. Sequentially, it rose 25.1% from the prior quarter. Over 3 fiscal years it compounded at -11.2% a year.
Context
- Research & development amounted to 33.1% of revenue in FY2025, down 27.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of -1.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.97M USD
- Year-over-year change
- -15.4%
- 4-year CAGR
- +1.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.97M | -15.4% |
| FY2024 | 2024-12-31 | 17.69M | -40.7% |
| FY2023 | 2023-12-31 | 29.84M | +39.7% |
| FY2022 | 2022-12-31 | 21.36M | +50.2% |
| FY2021 | 2021-12-31 | 14.22M | — |
Research & Development vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 research & development of $14.89M is the 8th highest of the 11 companies compared; the peer median is $19.01M.
- Its year-over-year change of -1.7% is the 6th highest of 11, against a peer median of -2.8%.
- Research & development amounts to 33.2% of revenue for TLSI, versus a peer median of 85.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.68M | +76.6% | +218.7% | 13864.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $24.4M | -23.4% | -12.2% | 824.8% | |
| LTM Mar 2026 | $21.15M | -1.0% | +12.6% | 112.1% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $18.78M | -12.5% | +2.2% | 58.2% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $14.89M | -1.7% | -11.2% | 33.2% | |
| LTM Mar 2026 | $6.33M | -47.4% | -11.0% | 4.2% | |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
| LTM Mar 2026 | $4.57M | -56.9% | -5.0% | 4.0% | |
| Peer median (excluding TLSI) | $19.01M | -2.8% | -7.6% | 85.1% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.